Gautam M. Borthakur

Hematology
1515 Holcombe Blvd Unit 428
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 503 publications

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica
Published: April 22, 2026

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Journal: Leukemia & lymphoma
Published: March 30, 2026

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Journal: Cancer
Published: March 30, 2026

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Journal: Journal of hematology & oncology
Published: March 25, 2026

Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission.

Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission.

Journal: Haematologica
Published: March 23, 2026

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Journal: Haematologica
Published: March 20, 2026

Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia.

Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia
Published: March 12, 2026

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 09, 2026

Ten-year long-term survivors of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Ten-year long-term survivors of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Journal: Leukemia & lymphoma
Published: February 19, 2026

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Journal: American journal of hematology
Published: February 09, 2026

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Journal: Cancer
Published: January 28, 2026

Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.

Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.

Journal: Blood advances
Published: January 23, 2026
Showing 1-12 of 503

Last Updated: 09/26/2026